Skip to main content

Table 1 Clinical features of patients with FCD IIb and TSC

From: Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex

Case no. Gender Age at surgery Diagnosis Seizure focus Epilepsy duration (year) Seizure frequency (per month) Engel’s class Application in the present study
1 F 7 FCD IIb F 5 45 I qPCR, WB, IHC,
2 F 1.8 FCD IIb F 1.2 105 II ELISA
3 M 3.5 FCD IIb T 3 65 I qPCR, WB, IHC,
4 F 7.5 FCD IIb F 6.5 30 I qPCR, WB, IHC,
5 M 5 FCD IIb T 4 80 II ELISA
6 M 4.3 FCD IIb O 3.5 120 I qPCR, WB, IHC,
7 F 9.5 FCD IIb P 8 25 I ELISIA
8 F 5.5 FCD IIb F 4 60 I qPCR, WB, IHC,
9 M 6 FCD IIb P 4.5 35 III qPCR, WB, IHC,
10 F 2 FCD IIb T 1 55 I qPCR, WB, IHC,
11 M 2.3 FCD IIb O 1.3 70 I qPCR, WB, IHC,
12 F 7 FCD IIb T 5.5 30 III ELISA
13 F 6 TSC P 4.8 60 I qPCR, WB, IHC,
14 M 2.1 TSC P 1.2 110 I qPCR, WB, IHC,
15 M 3.9 TSC T 3 82 I qPCR, WB, IHC,
16 F 7 TSC F 5.6 26 II ELISA
17 F 5.5 TSC T 4 48 I ELISA
18 F 4.8 TSC P 3.8 75 I qPCR, WB, IHC,
19 M 10 TSC T 8.1 30 I qPCR, WB, IHC,
20 F 6 TSC F 4.5 25 III ELISIA
21 M 5.5 TSC F 4 31 I qPCR, WB, IHC,
22 M 3 TSC T 2.3 55 I qPCR, WB, IHC,
23 M 1.5 TSC O 0.9 100 III qPCR, WB, IHC,
24 F 4 TSC P 2.9 50 I qPCR, WB, IHC,
25 F 3.5 TSC F 2.6 45 II ELISA
  1. F female, M male, FCD IIb focal cortical dysplasia type IIb, TSC tuberous sclerosis complex, F frontal lobe, O occipital lobe, P parietal lobe, T temporal lobe, ELISA enzyme-linked immune sorbent assay, qPCR quantitative real-time polymerase chain reaction, WB western blot, IHC immunohistochemistry (including double-labeled immunofluorescence)